Free Trial
→ I’m sounding the alarm (From Porter & Company) (Ad)tc pixel Free TCON Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

TRACON Pharmaceuticals (TCON) Competitors

TRACON Pharmaceuticals logo
Compare

TCON vs. ELOX, LIPO, ADTX, PTPI, and VINC

Should you be buying TRACON Pharmaceuticals stock or one of its competitors? The main competitors of TRACON Pharmaceuticals include Eloxx Pharmaceuticals (ELOX), Lipella Pharmaceuticals (LIPO), Aditxt (ADTX), Petros Pharmaceuticals (PTPI), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry.

How does TRACON Pharmaceuticals compare to Eloxx Pharmaceuticals?

TRACON Pharmaceuticals (NASDAQ:TCON) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

In the previous week, TRACON Pharmaceuticals' average media sentiment score of 0.00 equaled Eloxx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
TRACON Pharmaceuticals Neutral
Eloxx Pharmaceuticals Neutral

TRACON Pharmaceuticals has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$12.05M0.01-$3.59M$3.730.01
Eloxx PharmaceuticalsN/AN/A-$36.06M-$6.15N/A

Eloxx Pharmaceuticals' return on equity of 0.00% beat TRACON Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TRACON PharmaceuticalsN/A -237.65% 57.29%
Eloxx Pharmaceuticals N/A N/A N/A

TRACON Pharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, indicating that its stock price is 190,833% less volatile than the S&P 500.

11.6% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 5.3% of TRACON Pharmaceuticals shares are held by insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

TRACON Pharmaceuticals beats Eloxx Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does TRACON Pharmaceuticals compare to Lipella Pharmaceuticals?

TRACON Pharmaceuticals (NASDAQ:TCON) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, TRACON Pharmaceuticals' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
TRACON Pharmaceuticals Neutral
Lipella Pharmaceuticals Neutral

TRACON Pharmaceuticals has higher revenue and earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$12.05M0.01-$3.59M$3.730.01
Lipella Pharmaceuticals$536.36K0.23-$5.02M-$2.42N/A

TRACON Pharmaceuticals has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat TRACON Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TRACON PharmaceuticalsN/A -237.65% 57.29%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

TRACON Pharmaceuticals has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

11.6% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 5.3% of TRACON Pharmaceuticals shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

TRACON Pharmaceuticals beats Lipella Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does TRACON Pharmaceuticals compare to Aditxt?

TRACON Pharmaceuticals (NASDAQ:TCON) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Aditxt had 1 more articles in the media than TRACON Pharmaceuticals. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for TRACON Pharmaceuticals. TRACON Pharmaceuticals' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
TRACON Pharmaceuticals Neutral
Aditxt Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TRACON Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

TRACON Pharmaceuticals has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

TRACON Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -1,217,927.00%. TRACON Pharmaceuticals' return on equity of -237.65% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
TRACON PharmaceuticalsN/A -237.65% 57.29%
Aditxt -1,217,927.00%-374.60%-92.82%

11.6% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 5.3% of TRACON Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TRACON Pharmaceuticals has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$12.05M0.01-$3.59M$3.730.01
AditxtN/AN/A-$41.71M-$11.10 thousandN/A

Summary

TRACON Pharmaceuticals beats Aditxt on 9 of the 12 factors compared between the two stocks.

How does TRACON Pharmaceuticals compare to Petros Pharmaceuticals?

TRACON Pharmaceuticals (NASDAQ:TCON) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

TRACON Pharmaceuticals has higher revenue and earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$12.05M0.01-$3.59M$3.730.01
Petros Pharmaceuticals$5.11M0.04-$8.16M-$39.69N/A

Petros Pharmaceuticals' return on equity of -78.22% beat TRACON Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TRACON PharmaceuticalsN/A -237.65% 57.29%
Petros Pharmaceuticals N/A -78.22%-23.50%

TRACON Pharmaceuticals has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, TRACON Pharmaceuticals' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
TRACON Pharmaceuticals Neutral
Petros Pharmaceuticals Neutral

Summary

TRACON Pharmaceuticals and Petros Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does TRACON Pharmaceuticals compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled TRACON Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
TRACON Pharmaceuticals Neutral

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 5.3% of TRACON Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TRACON Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
TRACON Pharmaceuticals$12.05M0.01-$3.59M$3.730.01

Vincerx Pharma has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, TRACON Pharmaceuticals has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

TRACON Pharmaceuticals' return on equity of -237.65% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
TRACON Pharmaceuticals N/A -237.65%57.29%

Summary

TRACON Pharmaceuticals beats Vincerx Pharma on 6 of the 9 factors compared between the two stocks.

Get TRACON Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCON vs. The Competition

Export
MetricTRACON PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$110K$329.01M$6.25B$11.76B
Dividend YieldN/AN/A2.74%5.26%
P/E Ratio0.01N/A29.0227.07
Price / Sales0.01189.48499.0373.40
Price / Cash0.0222.4443.3053.90
Price / Book-0.094.739.656.69
Net Income-$3.59M-$132.96M$3.55B$332.64M

TRACON Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCON
TRACON Pharmaceuticals
N/A$0.03
flat		N/AN/A$110K$12.05M0.0120
ELOX
Eloxx Pharmaceuticals
N/A$0.12
flat		N/AN/A$377KN/AN/A30
LIPO
Lipella Pharmaceuticals
N/A$0.05
flat		N/A-99.0%$231K$536.36KN/A4
ADTX
Aditxt
0.884 of 5 stars		$0.22
-12.2%		N/A-100.0%$225K$3.20KN/A60
PTPI
Petros Pharmaceuticals
N/A$0.01
+1.4%		N/A-96.7%$224K$5.11MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TCON) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Revealed: The World’s First Trillion-Dollar Robot
Jensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...
Weiss Ratings | Sponsoredtc pixel
A U.S. Resource Gap Is a National Issue - and Opportunity
America still does not domestically produce one mineral tied to batteries, energy storage, and national defens...
i2i Marketing Group, LLC | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel